PMID- 26408707
OWN - NLM
STAT- MEDLINE
DCOM- 20160104
LR  - 20150926
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 35
IP  - 10
DP  - 2015 Oct
TI  - Signatures of Adverse Pathological Features, Androgen Insensitivity and 
      Metastatic Potential in Prostate Cancer.
PG  - 5443-51
AB  - BACKGROUND/AIM: The genetic characterization of prostate tumors is important for 
      personalized therapy. The aim of the present study was to investigate the role of 
      previously described prostate cancer-related genes in the genetic 
      characterization of prostate tumors. MATERIALS AND METHODS: Forty-two genes were 
      selected for expression analysis (real time-quantitative polymerase chain 
      reaction). One normal prostatic epithelial cell line and three standardized 
      prostate cancer cell lines were used. Twenty-eight patients treated with radical 
      prostatectomy were included in the study. RESULTS: The following genes appeared 
      to be possibly related to the metastatic potential of the tumor: ELOVL fatty acid 
      elongase 7 (ELOVL7), enhancer of zeste 2 polycomb repressive complex 2 subunit 
      (EZH2), gastrulation brain homeobox 2 (GBX2), golgi membrane protein 1 (GOLM1), 
      homeobox C6 (HOXC6), minichromosome maintenance complex component 6 (MCM6), 
      marker of proliferation Ki-67 (MKI67), mucin 1, cell surface associated (MUC1), 
      MYC binding protein 2, E3 ubiquitin protein ligase (MYCBP2), somatostatin 
      receptor 1 (SSTR1), topoisomerase (DNA) II alpha 170 kDa (TOP2A) and exportin 6 
      (XPO6). Six genes were differentially expressed in patients with localized and 
      locally advanced cancer (GOLM1, GBX2, XPO6, SSTR1, TOP2A and cell division cycle 
      associated 5, CDCA5) and three genes (HOXC6, Cyclin-dependent kinase inhibitor 2A 
      (CDKN2A) and MYC binding protein 2, E3 ubiquitin protein ligase, MYCBP2) in 
      patients with a low vs. high Gleason grade/sum. CONCLUSION: Some of the 
      investigated genes show promising prognostic and classification features, which 
      might be useful in a clinical setting, warranting for further validation.
CI  - Copyright(c) 2015 International Institute of Anticancer Research (Dr. John G. 
      Delinassios), All rights reserved.
FAU - Tolkach, Yuri
AU  - Tolkach Y
AD  - Clinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, 
      Germany.
FAU - Merseburger, Axel
AU  - Merseburger A
AD  - Clinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, 
      Germany.
FAU - Herrmann, Thomas
AU  - Herrmann T
AD  - Clinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, 
      Germany.
FAU - Kuczyk, Markus
AU  - Kuczyk M
AD  - Clinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, 
      Germany.
FAU - Serth, Jurgen
AU  - Serth J
AD  - Clinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, 
      Germany.
FAU - Imkamp, Florian
AU  - Imkamp F
AD  - Clinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, 
      Germany imkamp.florian@mh-hannover.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Aged
MH  - Cell Line, Tumor
MH  - Gene Expression Profiling/methods
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Metastasis
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Prostatectomy
MH  - Prostatic Neoplasms/*genetics/*pathology/surgery
OTO - NOTNLM
OT  - Prostate neoplasms
OT  - cell line
OT  - gene expression
OT  - radical prostatectomy
OT  - surgical pathology
EDAT- 2015/09/27 06:00
MHDA- 2016/01/05 06:00
CRDT- 2015/09/27 06:00
PHST- 2015/09/27 06:00 [entrez]
PHST- 2015/09/27 06:00 [pubmed]
PHST- 2016/01/05 06:00 [medline]
AID - 35/10/5443 [pii]
PST - ppublish
SO  - Anticancer Res. 2015 Oct;35(10):5443-51.